Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer
This phase II trial tests the effect of atezolizumab given with usual chemotherapy during
radiation therapy in treating patients with superior sulcus non-small cell lung cancer.
Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immu...
Age: 18 years - 66+
Gender: All
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative
This phase II/III trial compares the addition of radiation therapy to the usual treatment
(immunotherapy with or without chemotherapy) versus (vs.) usual treatment alone in treating
patients with non-small cell lung cancer that has spread to nearby tissue or lymph n...
Age: 18 years - 66+
Gender: All
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study
evaluating LN-145 in patients with metastatic non-small-cell lung cancer
Age: 18 - 70 years
Gender: All
Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning
This clinical trial tests a new mobile health application (app) called Planning Advance Care
Together (PACT) to help people with cancer talk about and plan for advance care planning (the
care they would want if they were unable to communicate) with their loved ones ...
Age: 18 years - 66+
Gender: All
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate the efficacy and safety of atezolizumab in
combination with tiragolumab compared with durvalumab in participants with locally advanced,
unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two
...
Age: 18 years - 66+
Gender: All
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm
the safety of VV1 in combination with cemiplimab. The study will enroll patients with two
distinct advanced malignancies in separate tumor cohorts. The two cancers types ar...
Age: 18 years - 66+
Gender: All
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer
This phase III trial studies how well atezolizumab added to the usual radiation therapy works
in treating patients with stage I-IIA non-small cell lung cancer. Immunotherapy with
monoclonal antibodies, such as atezolizumab, may help the body's immune system attack t...
Age: 18 years - 66+
Gender: All
Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
This trial studies how well the addition of targeted radiation therapy to surgery and the
usual chemotherapy treatment works for the treatment of stage I-IIIA malignant pleural
mesothelioma. Targeted radiation therapy such as intensity-modulated radiation therapy or...
Age: 18 - 80 years
Gender: All
Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)
The purpose of this research study is to study the effect of giving nivolumab with
CCR2/5-inhibitor or anti-IL-8 before surgery, and after surgery, with the goal of determining
if this medicine results in:
1. A significant immune response against their tumor (wh...
Age: 18 - 99 years
Gender: All
Assessing an Oral EGFR Inhibitor, DZD9008 in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
This study will treat patients with advanced NSCLC with EGFR or HER2 mutation who have
progressed following prior therapy. This is the first time this drug is tested in patients,
and so it will help to understand what type of side effects may occur with the drug
t...
Age: 18 years - 66+
Gender: All
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)
The purpose of this study is to assess the efficacy and safety of stereotactic body
radiotherapy (SBRT) plus pembrolizumab (MK-3475) in the treatment of adult participants with
unresected stage I or II (Stage IIB N0, M0) non-small cell lung cancer (NSCLC).
The p...
Age: 18 years - 66+
Gender: All
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
This screening and multi-sub-study randomized phase II/III trial will establish a method for
genomic screening of similar large cancer populations followed by assigning and accruing
simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of c...
Age: 18 years - 66+
Gender: All
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
This phase II/III trial studies how well chemotherapy and radiation therapy (chemoradiation)
with or without atezolizumab works in treating patients with limited stage small cell lung
cancer. Drugs used in chemotherapy, such as etoposide, cisplatin, and carboplatin,...
Age: 18 years - 66+
Gender: All
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed
by pemetrexed and carboplatin with or without pembrolizumab after disease progression is
superior to induction with pembrolizumab, pemetrexed and carboplatin followed by
p...
Age: 18 years - 66+
Gender: All
Collection of Sputum and Labeling for Lung Cancer
The primary objective of this study is to compare Assay results to diagnoses determined by
currently accepted standards for lung cancer detection. This will be accomplished by analysis
of sputum samples from three cohorts including healthy Participants, high risk Pa...
Age: 21 years - 66+
Gender: All
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
This phase I trial studies the side effects of pembrolizumab in treating patients with human
immunodeficiency virus (HIV) and malignant neoplasms that have come back (relapsed), do not
respond to treatment (refractory), or have distributed over a large area in the b...
Age: 18 years - 66+
Gender: All